Teva Pharmaceutical Industries Limited (TEVA)
The price, the headline numbers and the latest news, in one place.
Teva Pharmaceutical Industries Limited (TEVA) Stock Price, Analysis & Data
| Bid | 0 |
| Market Cap | 42.4B |
| Revenue (ttm) | 17.3B |
| Net Income (ttm) | 706M |
| 0.87 | |
| 0.6 | |
| 60.58 | |
| 11.84 | |
| P/B (ttm) | 5.46 |
| P/S (ttm) | 2.45 |
| Earnings Date | Nov 4, 2026 |
| Ask | 0 |
| Volume | 3,999,706 |
| Avg. Volume (20D) | 5,538,200 |
| Open | 36.82 |
| Previous Close | 36.76 |
| Day's Range | 36.47 - 37.31 |
| 52-Week Range | 18.21 - 38.37 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | Nov 27, 2017 |
About TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral...
Financial Performance
In 2025, Teva Pharmaceutical Industries's revenue was 17.26B, an increase of 4.31% compared to the previous year's 16.54B. Earnings were 1.41B, a decrease of -186.03%.
Financial StatementsEarnings Surprise
- Revenue of $4.14B misses estimates by $0, with -0.81% YoY decline.
- EPS of 0.02 misses estimates by -0.09, with -96.97% YoY decline.
Analysts project revenue of ... Upgrade
1 week ago · Schaeffer's Investment Research
Outperforming Pharma Stock Still Has Upside PotentialA historic bull signal is now flashing
1 week ago · Clinical Trials Arena
Teva’s mAb shows benefit in celiac disease studyWhile Teva announced positive Phase II data, it has not yet confirmed Phase III plans.